Enoxaparin and antifactor Xa levels in acute burn patients

Journal of Burn Care and Research

Volumn 32, Issue 1, 2011, Pages 1-5

  Lin, Hsin ^a   Faraklas, Iris ^a   Cochran, Amalia ^a   Saffle, Jeffrey ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN;

ACUTE BURN; ADOLESCENT; ADULT; AGED; ANTIFACTOR XA; ARTICLE; BLEEDING; BLOOD CLOTTING TEST; BURN; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; BURNS; ENOXAPARIN; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM;

EID: 79251487843     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e318204b346     Document Type: Article

References (16)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119 (1 Suppl):132S-75S.
2. Faucher L, Conlon K. Practice guideline for deep venous thrombosis prophylaxis in burns. J Burn Care Res 2007;28: 661-3.
3. Wibbenmeyer LA, Hoballah JJ, Amelon MJ, et al. The prevalence of venous thromboembolism of the lower extremity among thermally injured patients determined by duplex sonography. J Trauma 2003;55:1162-7.
4. Harrington DT, Mozingo DW, Canicio L, Bird P, Jordan B, Goodwin CW. Thermally injured patients are at significant risk for thromboembolic complications. J Trauma 2001;50:495-9.
5. Fecher AM, O'Mara MS, Goldfarb IW, et al. Analysis of deep vein thrombosis in burn patients. Burns 2004;30:591-3.
6. Wahl WL, Brandt MM, Ahrns KS, et al. Venous thrombosis incidence in burn patients: preliminary results of a prospective study. J Nurn Care Rehabil 2002;23:97-102.
7. Jaehde U, Sörgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 1995;29:15-28.
8. Bonate PL. Pathophysiology and pharmacokinetics following burn injury. Clin Pharmacokinet 1990;18:118-30.
9. Yogaratnam D, Smith BS, Angood PB, Gandhi PJ. Antifactor Xa levels in four patients with burn injury who received enoxaparin to prevent venous thromboembolism. Pharmacotherapy 2004;24:1793-9.
10. Cockcroft DW, Gault MH. Predication of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
11. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thomb Haemost 1989;62:940-4.
12. Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003;31: 1405-9.
13. Dörffler-Melly J, de Jonge E, de Pont A, et al. Bioavailability of subcutaneous low-molecular weight heparin to patients on vasopressors. Lancet 2002;359:849-50.
14. Haas CE, Nelsen JL, Raghavendran K, et al. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma 2005;59:1336-44.
15. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002;12:19-24.
16. Lott RS, Uden DL, Wargin WA, Strate RG, Zaske DE. Correlation of predicted versus measured creatinine clearance values in burn patients. Am J Hosp Pharm 1978;35:717-20.